Adaptive Biotechnologies guides FY2021 revenue $153M-$154M (+56% YoY); CFO Cohen to resign

Adaptive Biotechnologies Corp

2022-FY EPS reported -$1.48 revenue$154,344,000

FY2021 preliminary revenue $153M-$154M, up ~56% from $98.4M in 2020.
CFO Chad Cohen resigns effective ~Feb 15, 2022 after 10-K filing; no disagreement.
Principal Accounting Officer Kyle Piskel to serve as interim CFO; permanent search initiated.
Preliminary results subject to change; full results expected around Feb 15, 2022.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kyle Piskel

Chief Financial Officer

ADPT · Adaptive Biotechnologies Corp

Effective: 2022-02-15
Filed: January 10, 2022, 6:59 PM ET

after which Mr. Kyle Piskel, the Company’s Principal Accounting Officer, will act as Chief Financial Officer and principal financial officer.

Departed

Chad Cohen

Chief Financial Officer

ADPT · Adaptive Biotechnologies Corp

Effective: 2022-02-15
Successor: Kyle Piskel
Filed: January 10, 2022, 6:59 PM ET

On January 4, 2022, Chad Cohen, Chief Financial Officer of the Company, notified the Company of his decision to resign as Chief Financial Officer of the Company, effective following the filing of the Company’s Annual Report on Form 10-K for the period ended December 31, 2021, on or about February 15, 2022, after which Mr. Kyle Piskel, the Company’s Principal Accounting Officer, will act as Chief Financial Officer and principal financial officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Kyle Piskel was appointed as Chief Financial Officer at Adaptive Biotechnologies Corp.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

after which Mr. Kyle Piskel, the Company’s Principal Accounting Officer, will act as Chief Financial Officer and principal financial officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Chad Cohen resigned as Chief Financial Officer at Adaptive Biotechnologies Corp.

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On January 4, 2022, Chad Cohen, Chief Financial Officer of the Company, notified the Company of his decision to resign as Chief Financial Officer of the Company, effective following the filing of the Company’s Annual Report on Form 10-K for the period ended December 31, 2021, on or about February 15, 2022, after which Mr. Kyle Piskel, the Company’s Principal Accounting Officer, will act as Chief Financial Officer and principal financial officer.

View on SEC.gov

Adaptive Biotechnologies Corp filing history →

Source: SEC EDGAR

accession 0001564590-22-000785

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.